File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation

TitleCiprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation
Authors
Issue Date2005
PublisherOxford University Press. The Journal's web site is located at http://www.oxfordjournals.org/our_journals/cid/
Citation
Clinical Infectious Diseases, 2005, v. 40 n. 4, p. 528-537 How to Cite?
AbstractBackground. Polyoma BK virus (BKV) is associated with hemorrhagic cystitis during hematopoietic stem cell transplantation (HSCT). The objective of this study was to test whether standard-dose ciprofloxacin might suppress reactivation of BKV infection during HSCT. Methods. Sixty-eight patients received ciprofloxacin or a cephalosporin as antibiotic prophylaxis after undergoing allogeneic HSCT. Urine samples were collected weekly from day 7 before HSCT to day 50 after HSCT. Laboratory investigations included quantification of BKV load and urinary ciprofloxacin levels and in vitro drug sensitivity of BKV. Results. Twenty-two patients received ciprofloxacin, 21 received cephalosporins, 12 received concomitant corticosteroids and antibiotics (9 received ciprofloxacin, and 3 received cephalosporins), and 13 received interrupted ciprofloxacin therapy. Ciprofloxacin recipients developed a significantly lower peak BKV load, compared with cephalosporin recipients (median, 3 × 10 5 copies/mL vs.2.6 × 10 9 copies/mL; P = .021), irrespective of concomitant receipt of corticosteroid therapy. Fewer ciprofloxacin recipients than cephalosporin recipients (P = .013) developed BKV viruria with a ≥3-log increase in BKV load during HSCT, which was associated with significantly more cases of hemorrhagic cystitis (8 of 29 patients with a peak increase of ≥ log vs. 0 of 39 patients without a peak increase of this level; P < .001). Ciprofloxacin recipients excreted ciprofloxacin in urine at a mean 24-h rate of 71.7 μg/mL (range, 23.0-152.9 μg/mL), which was comparable with the in vitro inhibitory concentration of 125-250 μg/mL of ciprofloxacin found for 3 of 7 BKV isolates. Conclusions. Ciprofloxacin decreased urinary BKV reactivation after HSCT.
Persistent Identifierhttp://hdl.handle.net/10722/78508
ISSN
2015 Impact Factor: 8.736
2015 SCImago Journal Rankings: 4.742
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLeung, AYHen_HK
dc.contributor.authorChan, MTLen_HK
dc.contributor.authorYuen, KYen_HK
dc.contributor.authorCheng, VCCen_HK
dc.contributor.authorChan, KHen_HK
dc.contributor.authorWong, CLPen_HK
dc.contributor.authorLiang, Ren_HK
dc.contributor.authorLie, AKWen_HK
dc.contributor.authorKwong, YLen_HK
dc.date.accessioned2010-09-06T07:43:40Z-
dc.date.available2010-09-06T07:43:40Z-
dc.date.issued2005en_HK
dc.identifier.citationClinical Infectious Diseases, 2005, v. 40 n. 4, p. 528-537en_HK
dc.identifier.issn1058-4838en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78508-
dc.description.abstractBackground. Polyoma BK virus (BKV) is associated with hemorrhagic cystitis during hematopoietic stem cell transplantation (HSCT). The objective of this study was to test whether standard-dose ciprofloxacin might suppress reactivation of BKV infection during HSCT. Methods. Sixty-eight patients received ciprofloxacin or a cephalosporin as antibiotic prophylaxis after undergoing allogeneic HSCT. Urine samples were collected weekly from day 7 before HSCT to day 50 after HSCT. Laboratory investigations included quantification of BKV load and urinary ciprofloxacin levels and in vitro drug sensitivity of BKV. Results. Twenty-two patients received ciprofloxacin, 21 received cephalosporins, 12 received concomitant corticosteroids and antibiotics (9 received ciprofloxacin, and 3 received cephalosporins), and 13 received interrupted ciprofloxacin therapy. Ciprofloxacin recipients developed a significantly lower peak BKV load, compared with cephalosporin recipients (median, 3 × 10 5 copies/mL vs.2.6 × 10 9 copies/mL; P = .021), irrespective of concomitant receipt of corticosteroid therapy. Fewer ciprofloxacin recipients than cephalosporin recipients (P = .013) developed BKV viruria with a ≥3-log increase in BKV load during HSCT, which was associated with significantly more cases of hemorrhagic cystitis (8 of 29 patients with a peak increase of ≥ log vs. 0 of 39 patients without a peak increase of this level; P < .001). Ciprofloxacin recipients excreted ciprofloxacin in urine at a mean 24-h rate of 71.7 μg/mL (range, 23.0-152.9 μg/mL), which was comparable with the in vitro inhibitory concentration of 125-250 μg/mL of ciprofloxacin found for 3 of 7 BKV isolates. Conclusions. Ciprofloxacin decreased urinary BKV reactivation after HSCT.en_HK
dc.languageengen_HK
dc.publisherOxford University Press. The Journal's web site is located at http://www.oxfordjournals.org/our_journals/cid/en_HK
dc.relation.ispartofClinical Infectious Diseasesen_HK
dc.subject.meshAdolescenten_HK
dc.subject.meshAdulten_HK
dc.subject.meshAnti-Bacterial Agents - pharmacology - therapeutic useen_HK
dc.subject.meshAntibiotic Prophylaxisen_HK
dc.subject.meshBK Virus - isolation & purification - physiologyen_HK
dc.subject.meshCiprofloxacin - pharmacology - therapeutic useen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHematopoietic Stem Cell Transplantation - adverse effectsen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshPolyomavirus Infections - prevention & control - virologyen_HK
dc.subject.meshTransplantation, Homologous - adverse effectsen_HK
dc.subject.meshTumor Virus Infections - prevention & control - virologyen_HK
dc.subject.meshUrine - virologyen_HK
dc.subject.meshViral Loaden_HK
dc.subject.meshVirus Replication - drug effectsen_HK
dc.titleCiprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantationen_HK
dc.typeArticleen_HK
dc.identifier.emailLeung, AYH:ayhleung@hku.hken_HK
dc.identifier.emailYuen, KY:kyyuen@hkucc.hku.hken_HK
dc.identifier.emailLiang, R:rliang@hku.hken_HK
dc.identifier.emailKwong, YL:ylkwong@hku.hken_HK
dc.identifier.authorityLeung, AYH=rp00265en_HK
dc.identifier.authorityYuen, KY=rp00366en_HK
dc.identifier.authorityLiang, R=rp00345en_HK
dc.identifier.authorityKwong, YL=rp00358en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1086/427291en_HK
dc.identifier.pmid15712075en_HK
dc.identifier.scopuseid_2-s2.0-13944262482en_HK
dc.identifier.hkuros99034en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-13944262482&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume40en_HK
dc.identifier.issue4en_HK
dc.identifier.spage528en_HK
dc.identifier.epage537en_HK
dc.identifier.isiWOS:000227492600006-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLeung, AYH=7403012668en_HK
dc.identifier.scopusauthoridChan, MTL=36941301500en_HK
dc.identifier.scopusauthoridYuen, KY=36078079100en_HK
dc.identifier.scopusauthoridCheng, VCC=23670479400en_HK
dc.identifier.scopusauthoridChan, KH=7406034307en_HK
dc.identifier.scopusauthoridWong, CLP=16505759800en_HK
dc.identifier.scopusauthoridLiang, R=26643224900en_HK
dc.identifier.scopusauthoridLie, AKW=24284842400en_HK
dc.identifier.scopusauthoridKwong, YL=7102818954en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats